1333480-93-5

Upstream product

• 137-00-8 5-hydroxyethyl-4-methylthiazole 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 1333480-90-2 3-(2-tert-butoxy-2-oxoethyl)-5-(2-hydroxyethyl)-4-methylthiazol-3-ium bromide 
• 6313-36-6 benzyl thiosulphate 

Downstream Products

• 1333481-02-9 (S)-4-(N-(2-(1,2,3,4-tetra-O-trimethylsilyl-α-D-glucopyranosyl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate 
• 1333481-05-2 (S)-4-(N-(2-(α-D-glucopyranose-6-yl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate 
• 1333480-96-8 (S)-4-(N-(2-tert-butoxy-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate 
• 1617540-47-2 C₃₁H₃₇NO₄S₂Si 
• 1617540-46-1 C₃₅H₄₅NO₄S₂Si 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen

Glucosyl derivates exhibited favorable distribution to the brain. However, bidirectional transport of glucose transporter 1 might decrease concentrations of the prodrugs in brain before the release of parent drugs. To overcome this defect, glucosyl thiamine disulfide prodrugs 1a-1c incorporating naproxen were designed and synthesized. Furthermore, prodrug 2 and 3 were also prepared as control. The favorable physicochemical properties of these prodrugs were verified by stability and metabolism studies. Results from the in vivo distribution study indicated that 1a-1c, and 1b in particular, significantly increased the level of naproxen in brain when compared to 2 and 3. The study suggested glucosyl thiamine disulfide was a promising carrier to enhance the brain bioavailability of central nervous system active drugs.

Novel glucose-based brain-targeting prodrug with locking function

The invention discloses a novel glucose-based TDS modified brain-targeting prodrug with a locking function. The prodrug is of a structure shown in a general formula (I) (described in the specification) or pharmaceutically acceptable salt of hydrate of the structure, wherein X is -NH-(CH2)m-O-, -NH-(CH2)m-NH-, -C(O)-(CH2)m-NH-, -C(O)-(CH2)m-O-, -O-(CH2)m-O-, -O-(CH2)m-NH-; Y is -C(O)-(CH2)n-C(O)-; m represents 2-6, n represents 1-4; Drug is a drug acting on a central nervous system. A series of prodrugs provided by the invention, on the basis of glucose brain targeting, are added with a TDS part, so that the prodrugs have the locking function, brain targeting and center concentration of the drug can be improved, the curative effect of the drug is enhanced, and distribution of the drug in peripheral organs is reduced while toxic and side effects of the drug are reduced.

Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with "lock-in" function

A novel brain targeting l-ascorbic acid derivatives with "lock-in" function were designed and synthesized as prodrugs to achieve the effective delivery of ibuprofen to brain by glucose transporter 1 (GLUT1) and the Na+-dependent vitamin C transporter SVCT2. Ibuprofen-loaded four prodrugs were tested in the animals. Results from the in vivo distribution study after i.v. administration of these four prodrugs and naked ibuprofen indicated that four prodrugs exhibited excellent transport ability across the BBB and significantly increased the level of ibuprofen in brain. Among them, prodrugs 4 showed higher brain concentration. Both biodistribution data and pharmacokinetic parameters suggested that l-ascorbic acid thiamine disulfide delivery system was a promising carrier to enhance CNS drug's delivery ability into brain.